Earnings
uniQure CEO Vows To Finish Huntington's Trial Even If FDA Rejects Its Gene Therapy
CEO Matt Kapusta calls the study an ethical obligation, with an FDA decision on AMT-130 targeted for May 1, 2027.
uniQure (QURE) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
CEO Matt Kapusta calls the study an ethical obligation, with an FDA decision on AMT-130 targeted for May 1, 2027.
SEC Filings
The gene therapy maker's quarterly report says the 48-month readout was left out of its FDA filing, now under priority review with a May 1, 2027 target date.
Markets
The Huntington's gene therapy now has a May 1, 2027 FDA target date, but shares gave up an early gain at Monday's close.
SEC Filings
The agency granted Priority Review to ifezuntirgene inilparvovec and tentatively plans an advisory committee meeting, uniQure said.
SEC Filings
Four-year data on AMT-130 fell well short of the 80% slowing reported in the updated three-year analysis, complicating a biologics license application already before the FDA.